

Supplementary Figure 1. Flow chart of eligibility of ESCC samples.



Supplementary Figure 2. Mutation spectrum of 94 ESCC detected by whole-genome sequencing. (a) The number of mutations in different genomic regions of 94 ESCC samples. Data represent mean  $\pm$  s.e.m. of mutations per sample (y axis) by type of genomic regions (x axis). CDS, coding sequence. (b) The number of mutations per megabase in different genomic regions of 94 ESCC samples. Data represent mean  $\pm$  s.e.m. of mutations (y axis) by type of genomic regions (x axis). (c) One example of kataegis of ESCC\_191. The 'rainfall' plot represents an individual ESCC sample in which each dot represents a single somatic mutation ordered on the horizontal axis according to its position in the human genome. The vertical axis denotes the genomic distance of each mutation from the previous mutation. (d) Comparison of *APOBEC3B* and *APOBEC3C* mRNA expression in tumor and normal samples (*P*-values were obtained by Student's *t*-test) and correlation of *APOBEC3B* and *APOBEC3C* mRNA expression and number of APOBEC signature mutations. The *APOBEC3B* or *APOBEC3C* mRNA expression (RSEM) was added by 1 and then log2 transformed.



Supplementary Figure 3. Signature stability and reconstruction error of non-negative-matrix factorization analysis. Non-negative-matrix factorizations with different numbers of signatures were tried, from three to eight. The y axis represents reconstruction error (*left*) and signature stability (*right*).



**Supplementary Figure 4.** Associations between mutational signatures and age at ESCC diagnosis or smoking status. The y axis denotes number of mutations. Mutational Signatures E3 and E5 were significantly associated with age at ESCC diagnosis (a), while Mutational Signatures E3 and E4 were significantly associated with tobacco smoking (b). No significant association of mutation number was detected in other previously reported studies (c). Data are presented in Tukey's boxplot. The line in the middle of the box is plotted at the median while the upper and lower hinges represent 25th and 75th percentiles. Whiskers indicate1.5 times interquartile range (IQR) and values greater than it are plotted as individual points. The minima and maxima are the lowest datum still within 1.5 IQR of the lower quartile and the highest datum still within 1.5 IQR of the upper quartile. *P*-values were obtained by unpaired Wilcox rank-sum test. ns, not significant.



**Supplementary Figure 5. Transcriptional bias of mutational Signature E4.** (a) Mutations are clustered into six types (y axis) and number of mutations in each type (x axis) is shown. Mutations on the transcribed strand are displayed in blue while mutations on the untranscribed strand are displayed in red. (b) Mutational signature is displayed using a 192-substitution classification incorporating the substitution type, the sequence context immediately 5' and 3' to the mutated base and whether the mutated base is on the transcribed or untranscribed strand (x axis). The panels for each of the six types of substitutions as well as the mutated base are displayed in different colors. The mutation fractions for each type are shown in y axis. Mutations on the transcribed strand are displayed in blue while mutations on the untranscribed strand are displayed in blue while mutations on the untranscribed strand are displayed in blue while mutations on the untranscribed strand are displayed in blue while mutations on the untranscribed strand are displayed in red.



Supplementary Figure 6. Mutation frequencies and significantly mutated genes in 94 ESCC detected by whole-genome sequencing. Significantly mutated genes (identified using the MutSigCV algorithm; FDR q<0.5) ordered by q value; additional genes (P<0.01) with trends towards significance are also shown. Samples are arranged to emphasize mutual exclusivity among mutations. Each column denotes an individual tumor, and each row represents a gene. *Top*, key clinical parameters of each examined case. *Right*, mutation percentage (x axis) and number of mutations (y axis) for each gene in 94 ESCC. Clinical characteristics and mutation types are shown by color as indicated.



**Supplementary Figure 7. Schematics of protein alterations for 20 significantly mutated ESCC driver genes.** Known functional domains of each protein are mapped from the UniProt. The predicted impact of mutations is shown by a filled colored circle and stick. The color code is as follows: green = missense, red = frame shift indel & nonsense & splice site, black = in frame indel, grey = silent, and purple = multiple mutations. The height of the lollipop is the number of mutations at a position. The most frequent mutation is labeled with its amino acid change. The figures are created using the cBioPortal mutation mapper with manual coloring of the mutations.



**Supplementary Figure 8. Integrative analysis of mutation type, copy number and mRNA expression of predicted driver genes in ESCC.** Nineteen driver genes (except *KDM6A*, located on chromosome X) are ordered by *q*-value. x axis represents discrete DNA copy number values while y axis represents mRNA expression measurements. Mutations are indicated as follows: red = missense, grey = nonsense, yellow ochre = frame shift indel, blue = in frame indel, green = splice site, hot pink = silent and purple = multiple mutations in single sample. Black indicates wild type sequence. DNA copy number status is coded as follows: HD = homozygous deletion, LOH = heterozygous deletion, N = copy neutral, Am1 = single copy gain, Am2 = multiple copy gain.



Supplementary Figure 9. Functional analysis of significantly mutated CUL3 and RBPJ genes. (a) Knockdown or overexpression of the CUL3 and RBPJ genes in ESCC cells. Significant knockdown of the expression of the two genes by siRNA (*upper panel*) and ectopic overexpression of the two genes by transfection of pcDNA3.1-CUL3 and pcDNA3.1-RBPJ in ESCC cells (*lower panel*). The data represent mean ± s.e.m of mRNA expression from three independent experiments and each had three replications. (b) Effects of knockdown or overexpression of CUL3 and RBPJ on ESCC cell proliferation. Data represent mean ± s.e.m of OD<sub>450</sub> values from three independent experiments and each had three replications. \*, *P*<0.01 compared with control by Student's *t*-test. (c) Effects of knockdown or overexpression of CUL3 and RBPJ on ESCC cell migration and invasion (*upper panel*). Data (*lower panel*) represent mean ± s.e.m. of cell number from three independent experiments and each had duplication. \*, *P*<0.01 by Student's *t*-test as compared with siRNA control or pcDNA3.1 vector control. Scale bars,100 µm.



**Supplementary Figure 10. Comparison of mutations in ESCC and other types of cancer.** (a) Hierarchical clustering using the mutation frequency of 20 ESCC driver genes in ESCC, HNSCC, LUSCC and EAC. (b) Significant driver gene that is unique or common in different cancer types. Driver genes in HNSCC, LUSCC and EAC are derived from tumor portal (http://www.tumorportal.org).



Supplementary Figure 11. Significant mutations in the non-coding regions in ESCC. (a) mutations in four long non-coding RNAs. (b) Mutations in the promoter region of the *FCMR* gene. (c & d) Mutations in the 3'-untraslated regions (3'UTR) of the *FOXJ3* and *CLOCK* genes.

•

•



Supplementary Figure 12. Effects of mutations in the 3'-untranslated regions of *FOXJ3* (a) and *CLOCK* (b) on their mRNA expression. Data are mean  $\pm$  s.d. and the *P*-values were obtained by unpaired Student's *t*-test.



**Supplementary Figure 13. Hierarchical clustering and PCA analysis of copy number alteration and mRNA expression in ESCC and other cancers.** Data are from 94 ESCC, 519 HNSCC, 512 LUSCC, 439 STAD and 79 EAC samples. (a) Hierarchical clustering were performed using the arm-level alteration frequency with Euclidean distance under the Ward's method for different cancer types (x axis). The heat map shows the frequency of chromosomal copy gains (upper) and losses (lower) ordered from chromosome 1p to 22q (y axis). (b) PCA was performed using whole genome copy number profiles. (c) The expression of top 6,000 most variable genes was obtained and log2 transformed followed by gene mean centering. Hierarchical clustering was performed using the average linkage algorithm with 1 minus Pearson correlation coefficient as the dissimilarity measure. (d) PCA was performed using the log2 transformed expression of the top 6,000 most variable genes.



Supplementary Figure 14. Correlation between copy number change and mRNA expression in 57 significant peak regions of focal genomic alterations. Spearman's correlation P (*upper*) and r values (*lower*) between copy number and expression of genes (y axis) are shown. Genes are ordered by their chromosome positions (x axis). Black lines indicate P=0.05 (*upper*) and r=0.3 (*lower*).



Supplementary Figure 15. Correlations between copy number change and mRNA expression of 7 genes commonly amplified in three squamous cell cancers. Gene expression (RSEM) are shown in y axis. Putative copy number in x axis (see Supplementary Data 11) are estimated by the GISTIC 2.0 (all\_data\_by\_genes.txt) with copy number as a continuous variable.



Supplementary Figure 16. Correlations between copy number change and mRNA expression of 7 genes commonly deleted in three squamous cell cancers. Gene expression are showed in y axis. Putative copy number in x axis (see Supplementary Data 11) are estimated by the GISTIC 2.0 (all\_data\_by\_genes.txt) with copy number as a continuous variable.



**Supplementary Figure 17. Correlations between copy number change and mRNA expression of 14 genes commonly observed in three squamous cell cancers.** Gene expression are shown in y axis. Putative copy number in x axis (see Supplementary Data 11) are estimated by the GISTIC 2.0 (all\_thresholded.by\_genes.txt) with copy number as a categorical variable. Tumor types are denoted by color as indicated. Data are presented in Tukey's boxplot. The line in the middle of the box is plotted at median while the upper and lower hinges represent 25th and 75th percentiles. Whiskers indicate 1.5 times interquartile range (IQR) and values greater than it are plotted as individual points. The minima and maxima are the lowest datum still within 1.5 IQR of the lower quartile and the highest datum still within 1.5 IQR of the upper quartile.



Supplementary Figure 18. Functional analysis of 14 genes affected by copy number alteration commonly observed in three types of squamous cell cancer. (a) Knockdown of the expression of the 14 genes in three SCC cell lines by siRNA. Data represent mean  $\pm$  s.e.m. of mRNA expression from three independent experiments and each had triplication. (b) Effects of knockdown of the 14 genes on SCC cell migration and invasion. Shown are typical cell migration and invasion pictures; quantitative data are presented in Figure 3c in the main text. Scale bars,100 µm.



Supplementary Figure 19. Effects of knockdown of 7 genes with copy number gain on SCC cell proliferation. Line in blue represents siRNA and line in red represents scramble RNA. Data represent mean  $\pm$  s.e.m. of OD<sub>450</sub> values from three independent experiments and each had triplication. \*, *P*<0.01 by Student's *t*-test compared with scramble RNA.



Supplementary Figure 20. Effects of knockdown of 7 genes with copy number loss on SCC cell proliferation. Line in blue represents siRNA and line in red represents scramble RNA. Data represent mean  $\pm$  s.e.m. of OD<sub>450</sub> values from three independent experiments and each had triplication. Line in blue represents siRNA and line in red represents scramble RNA. \*, *P*<0.01 by Student's *t*-test compared with scramble RNA.



**Supplementary Figure 21. Circos plots show chromothripsis in 13 ESCC samples.** Chromosomes are shown with different colors and in a circular form. The inner ring represents the copy number variations (red = gain and blue = loss). Lines traversing the ring connects break points of SVs. Sample with chromothripsis shows an extreme amount of rearrangements on one or a few chromosomes.



**Supplementary Figure 22. Principal component analysis of RNA expression data.** Shown are the first two principal components for RNA expression from RNA sequencing data.

|                 | P value* |        |        |  |  |
|-----------------|----------|--------|--------|--|--|
|                 | SNV      | Indel  | SV     |  |  |
| Age             | 0.3702   | 0.2227 | 0.6573 |  |  |
| Gender          | 0.5249   | 0.3483 | 0.0248 |  |  |
| Smoking status  | 0.4916   | 0.2238 | 0.6212 |  |  |
| Drinking status | 0.2863   | 0.4998 | 0.4825 |  |  |
| TP53 mutation   | 0.0001   | 0.0798 | 0.8253 |  |  |

Supplementary Table 1. Correlations between mutation or structure variation and clinical phenotype

\*Student's *t*-test.

| Sample ID | Chromosome | Arm | Start     | End       | Number of mutation | Nearby SV     |
|-----------|------------|-----|-----------|-----------|--------------------|---------------|
| ESCC_12   | 11         | q   | 93729585  | 93731670  | 8                  |               |
| ESCC_131  | Y          | р   | 8359558   | 8436129   | 8                  | translocation |
| ESCC_142  | 3          | q   | 172859671 | 172861401 | 8                  |               |
| ESCC_16   | 1          | р   | 18566790  | 18569466  | 6                  |               |
| ESCC_16   | 5          | q   | 95340931  | 95343787  | 9                  |               |
| ESCC_169  | 5          | q   | 55606291  | 55610731  | 8                  | inversion     |
| ESCC_179  | 15         | q   | 100989354 | 100991568 | 6                  |               |
| ESCC_191  | 1          | q   | 226196010 | 226197541 | 6                  |               |
| ESCC_191  | 6          | р   | 31645348  | 31647289  | 7                  |               |
| ESCC_191  | 18         | q   | 23029028  | 23029990  | 11                 | translocation |
| ESCC_208  | 2          | q   | 119478549 | 119484512 | 13                 |               |
| ESCC_208  | 6          | р   | 7507845   | 7523858   | 22                 |               |
| ESCC_208  | 10         | q   | 62385187  | 62389337  | 7                  |               |
| ESCC_E3   | 9          | р   | 36380923  | 36386866  | 8                  |               |
| ESCC_E3   | 13         | q   | 23148278  | 23168312  | 20                 | translocation |

Supplementary Table 2. Kataegis events identified in ESCC samples

| ESCC<br>(this study) | COSMIC<br>(Alexandrov <i>et al</i> .) | Cosine similarity | Correlation with              |
|----------------------|---------------------------------------|-------------------|-------------------------------|
| WEC Signature E1     | Signature 2                           | 0.819             | APOBEC                        |
| WES Signature ET     | Signature 13                          | 0.813             | APOBEC                        |
| WES Signature E2     | Signature 4                           | 0.860             | Smoking                       |
|                      | Signature 1A                          | 0.829             | Age                           |
| MEC Signature E2     | Signature 1B                          | 0.783             | Age                           |
| WES Signature E3     | Signature 6                           | 0.939             | Defective DNA mismatch repair |
|                      | Signature 15                          | 0.862             | Defective DNA mismatch repair |
| WES Signature E4     | Signature 16                          | 0.873             | Unknown                       |
|                      | Signature 1A                          | 0.838             | Age                           |
|                      | Signature 1B                          | 0.892             | Age                           |
| WES Signature ES     | Signature 6                           | 0.915             | Defective DNA mismatch repair |
|                      | Signature 15                          | 0.826             | Defective DNA mismatch repair |
| WES Signature E6     |                                       |                   |                               |

Supplementary Table 3. Similarity between the mutational signatures in this study and in COSMIC

| Chromosome | Start     | End       | Region type  | Gene        | Target region<br>mutation<br>number | Target region<br>length | P value*               | <i>q</i> value <sup>#</sup> |
|------------|-----------|-----------|--------------|-------------|-------------------------------------|-------------------------|------------------------|-----------------------------|
| chr11      | 65190269  | 65213011  | lincRNA_exon | NEAT1       | 6                                   | 22742                   | 2.71×10 <sup>-28</sup> | 5.92×10 <sup>-25</sup>      |
| chr1       | 73801129  | 73804560  | lincRNA_exon | LINC01360   | 4                                   | 3431                    | 1.46×10 <sup>-18</sup> | 8.00×10 <sup>-16</sup>      |
| chr5       | 59816847  | 59822245  | lincRNA_exon | PART1       | 4                                   | 5398                    | 1.46×10 <sup>-18</sup> | 8.00×10 <sup>-16</sup>      |
| chr22      | 48312477  | 48322013  | lincRNA_exon | CTA-280A3.2 | 4                                   | 9536                    | 1.46×10 <sup>-18</sup> | 8.00×10 <sup>-16</sup>      |
| chr1       | 207096343 | 207098592 | promoter     | FCMR        | 5                                   | 2250                    | 4.39×10 <sup>-17</sup> | 2.17×10 <sup>-13</sup>      |
| chr18      | 45335328  | 45368200  | 3UTR         | SMAD2       | 7                                   | 32873                   | 3.23×10 <sup>-41</sup> | 1.00×10 <sup>-37</sup>      |
| chr2       | 32530693  | 32541663  | 3UTR         | YIPF4       | 5                                   | 10971                   | 4.65×10 <sup>-29</sup> | 4.81×10 <sup>-26</sup>      |
| chr12      | 133494894 | 133501961 | 3UTR         | ZNF605      | 5                                   | 7068                    | 4.65×10 <sup>-29</sup> | 4.81×10 <sup>-26</sup>      |
| chr1       | 42642210  | 42645383  | 3UTR         | FOXJ3       | 4                                   | 3174                    | 4.23×10 <sup>-23</sup> | 1.31×10 <sup>-20</sup>      |
| chr2       | 192550492 | 192561385 | 3UTR         | NABP1       | 4                                   | 10894                   | 4.23×10 <sup>-23</sup> | 1.31×10 <sup>-20</sup>      |
| chr4       | 56294070  | 56301584  | 3UTR         | CLOCK       | 4                                   | 7515                    | 4.23×10 <sup>-23</sup> | 1.31×10 <sup>-20</sup>      |
| chr4       | 69176105  | 69179819  | 3UTR         | YTHDC1      | 4                                   | 3715                    | 4.23×10 <sup>-23</sup> | 1.31×10 <sup>-20</sup>      |
| chr7       | 141170584 | 141180180 | 3UTR         | TMEM178B    | 4                                   | 9597                    | 4.23×10 <sup>-23</sup> | 1.31×10 <sup>-20</sup>      |
| chr18      | 60052265  | 60058525  | 3UTR         | TNFRSF11A   | 4                                   | 6261                    | 4.23×10 <sup>-23</sup> | 1.31×10 <sup>-20</sup>      |
| chr18      | 74980856  | 74989852  | 3UTR         | GALR1       | 4                                   | 8997                    | 4.23×10 <sup>-23</sup> | 1.31×10 <sup>-20</sup>      |

Supplementary Table 4. Somatic mutations in the non-coding regions identified by whole-genome sequencing

\**P* values were calculated by a regional recurrence testing approach.

<sup>#</sup>FDR (false discovery rate).

| Fusion genes | Fusion<br>sample | Break point                         | Forward primer (5'→3')   | Reverse primer (5'→3')    |
|--------------|------------------|-------------------------------------|--------------------------|---------------------------|
| ERC1-WNK1    | ESCC_240         | chr12:1299718<br>and chr12:968952   | TATCATTAAGCAAAAAAGCAGTT  | CAAGTCTACCACTAACCCCAAA    |
| RAD52-ERC1   | ESCC_142         | chr12:1052385<br>and chr12:1326966  | ACACACCACACCCATCAGAATAA  | AGAAACTTTGAGTGGAGGCGAA    |
| PRAF2-ERC1   | ESCC_220         | chrX:48931714<br>and chr12:1464097  | TTGGTTTGGTAGTAGAGGAGGTTG | TTCTATGGCTACGCTGGTGCT     |
| NRG1-ZCCHC7  | ESCC_156         | chr8:31523079<br>and chr9:37341603  | ACCAGTTTGCCTTTATGACCTTC  | TCTCCTACTACTTTCCCTCACAGC  |
| WT1-MRPL19   | ESCC_243         | chr11:32414334<br>and chr2:75884322 | CCAGCAATGAGAAGTGAACCTA   | CAGCAAATAATCTAAACAAGTGAAG |

Supplementary Table 5. Primers used for validation of gene fusions by PCR-Sanger sequencing

|                      | No. (%)   |  |
|----------------------|-----------|--|
| Gender               |           |  |
| Male                 | 83 (88.3) |  |
| Female               | 11 (11.7) |  |
| Age                  |           |  |
| < 60                 | 42 (44.7) |  |
| ≥ 60                 | 52 (55.3) |  |
| Smoking status       |           |  |
| Smoker               | 77 (81.9) |  |
| Non-smoker           | 17 (18.1) |  |
| Drinking status      |           |  |
| Drinker              | 74 (78.7) |  |
| Non-drinker          | 20 (21.3) |  |
| Tumor location*      |           |  |
| Upper                | 0         |  |
| Middle               | 31 (33.0) |  |
| Lower                | 26 (27.7) |  |
| Middle and Lower     | 37 (39.3) |  |
| Stage                |           |  |
| I                    | 0         |  |
| II                   | 26 (27.6) |  |
| 111                  | 67 (71.3) |  |
| IV                   | 1 (1.1)   |  |
| T stage <sup>#</sup> |           |  |
| Τ1                   | 0         |  |
| T2                   | 13 (13.8) |  |
| Т3                   | 42 (44.7) |  |
| Τ4                   | 39 (41.5) |  |
| N stage <sup>#</sup> |           |  |
| NO                   | 30 (31.9) |  |
| N1                   | 26 (27.7) |  |
| N2                   | 25 (26.6) |  |
| N3                   | 13 (13.8) |  |
| M stage <sup>#</sup> |           |  |
| MO                   | 93 (98.9) |  |
| M1                   | 1 (1.1)   |  |
| Survival status      |           |  |
| Deceased             | 62 (66.0) |  |
| Alive                | 32 (34.0) |  |

\*Tumor locations were classified into three regions by the distance from the incisor to the tumor. Upper, 20-25 cm; middle, 25-30 cm and lower, 30-40 cm.

<sup>#</sup>Tumor TNM stages were determined according to the 7th edition of AJCC TNM staging system of ESCC.

| Gene ID | Symbol   | Forward primer (5'→3')   | Reverse primer (5'→3')   |
|---------|----------|--------------------------|--------------------------|
| 8452    | CUL3     | TCGACAGCTCACACTCCAGCAT   | GTGCTTCCGTGTATTAGAGCCAG  |
| 3516    | RBPJ     | TCATGCCAGTTCACAGCAGTGG   | TGGATGTAGCCATCTCGGACTG   |
| 374868  | ATP9B    | GAGAATCGCACCTACCAGGCTT   | GAATGCAGAAGCTGAGGACCTG   |
| 65980   | BRD9     | GCGACTTGAAGTCGGACGAGAT   | GTCCACCACTTTCTTGCTGTAGC  |
| 10576   | CCT2     | GCTCACAGTGAAGGCAATACCAC  | GCACTCAGAAGAACCTGTCGCT   |
| 55722   | CEP72    | GGCGAGATTGTGGAACTGAAGC   | GCAGGTGTTCATTGGTGCTGAC   |
| 81037   | CLPTM1L  | GGAAAACCGTGCATTACCTGCC   | CAGTGAGACCTTGTCGTAGGAC   |
| 51084   | CRYL1    | TGCTGTTTGCCAGTGGAGGCTT   | GAGCCTTTCAGAGAACCTGCCT   |
| 56940   | DUSP22   | TGACCGTCACTGACTTTGGCTG   | CTTCCTTCAGCCACTGCCGATA   |
| 1956    | EGFR     | CAGATGGATGTGAACCCCGA     | CGTAGCATTTATGGAGAGTGAGTC |
| 9208    | LRRFIP1  | GAGAGACTTCCGACACCCTCAA   | CACCTCCACTTCACTGGCTCTT   |
| 58508   | MLL3     | AGATCAGCGTGGACCCTATCCT   | CTCTTGACTCGGCATGGTACCA   |
| 54737   | MPHOSPH8 | CTCCTCATCACAAAAGGCGCGA   | CAGTCTCACCATTGCTTTGCTGG  |
| 8500    | PPFIA1   | AGCCATGATGCTTCAGGAGCAG   | GACTTCCACTGCCAACTCGACT   |
| 80148   | PQLC1    | ACCTACCTGTCCATTGACTCCG   | GGTCCACATGAGCACCATCTTG   |
| 8089    | YEATS4   | GCTGTTTCAATCAGACACCAATGC | GGCTCCTAATGTTAGCTGACGAG  |
| 2597    | GAPDH    | TTGGCCAGGGGTGCTAAG       | AGCCAAAAGGGTCATCATCTC    |

Supplementary Table 7. Primers used for quantitative real-time PCR